QPPV.COM KNOWLEDGE ASSESSMENT

Bevacizumab: Classification, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Bevacizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which combination best represents the multidimensional classification of bevacizumab?

Humanised IgG1 monoclonal antibody, recombinant glycoprotein, VEGF-A ligand neutraliser and anti-angiogenic antineoplastic Murine IgG antibody, antibody-drug conjugate and intracellular kinase inhibitor Fully synthetic small molecule, VEGFR agonist and cytotoxic chemotherapy Humanised antibody directed against a tumour-cell antigen with a covalently attached toxin

Question 2 of 10 A patient develops a serious adverse event after switching between two bevacizumab products. How should delayed-event attribution be approached?

Map the complete exposure history, including all products, doses, batches and timing, rather than assigning the event automatically to the latest product Attribute the event automatically to the product administered most recently Exclude the event from analysis because more than one product was used Attribute the event only to the product with the largest market share

Question 3 of 10 Why can bevacizumab produce clinically important effects in tumours that do not express a specific tumour-cell surface antigen targeted by the antibody?

Its principal target is the host and tumour vascular interface rather than a required malignant-cell antigen It enters tumour cells and replaces defective DNA repair proteins It activates antibody-dependent cellular cytotoxicity against every tumour type It directly inhibits all intracellular signalling in malignant cells

Question 4 of 10 Which intervention best demonstrates effective risk minimisation for bevacizumab-associated wound complications?

Coordinating oncology and surgical teams to apply product-specific perioperative timing and confirming adequate healing before restart Providing general written warnings without documenting whether timing recommendations were followed Restarting treatment immediately after surgery whenever the patient has no fever Omitting bevacizumab from medication reconciliation because it is administered by infusion

Question 5 of 10 Which description best distinguishes bevacizumab from a VEGF-receptor tyrosine kinase inhibitor?

Bevacizumab binds VEGF-A extracellularly and reduces ligand availability to VEGFR-1 and VEGFR-2 Bevacizumab irreversibly inhibits the intracellular kinase domains of VEGFR-1 and VEGFR-2 Bevacizumab binds a tumour-cell antigen and delivers a cytotoxic payload Bevacizumab blocks all ligands in the VEGF ligand family equally

Question 6 of 10 A radiographic lesion shows substantially less contrast enhancement shortly after bevacizumab treatment. What is the most cautious interpretation?

The change may partly reflect reduced vascular permeability and does not by itself establish an equivalent reduction in viable tumour The finding proves resistance because contrast enhancement has decreased The finding proves that all tumour vessels have regressed permanently The finding can only be attributed to direct tumour-cell killing

Question 7 of 10 Several reports of endophthalmitis occur among patients who received intravitreal bevacizumab aliquots prepared from the same source. What should be prioritised?

Investigation of the preparation and handling chain, including compounder, storage, source lot and microbiological findings Pooling the cases with intravenous oncology hypertension reports because the active substance is the same Assuming the cluster represents a class-wide systemic vascular reaction Excluding the cases because intravitreal use is not an authorised Avastin route

Question 8 of 10 Which statement best reflects the regulatory significance of bevacizumab's development across tumour types?

Evidence of efficacy in one cancer, regimen and jurisdiction cannot automatically be extrapolated to every other indication Presence of VEGF in a tumour is sufficient to establish benefit for every tumour type Once a molecule is authorised anywhere, all uses become intrinsically authorised everywhere Safety and efficacy conclusions are independent of the accompanying chemotherapy regimen

Question 9 of 10 Which pregnancy case information is most important for evaluating potential bevacizumab-related fetal risk?

Dose dates in relation to conception and gestational age, co-therapy, ultrasound findings and pregnancy outcome Only whether the patient experienced nausea during treatment The patient's tumour response without any reproductive chronology The brand name without dose, timing or outcome information

Question 10 of 10 Why should a report of severe proteinuria during bevacizumab treatment include serial quantitative measurements rather than only the coded term 'proteinuria'?

Serial quantitative data help establish onset, severity, response, recurrence and possible renal complications Coding terms are sufficient because proteinuria has no relationship to dose or time Quantification is relevant only for intravitreal administration A single coded term determines whether the injury is thrombotic microangiopathy

QPPV.com

Bevacizumab: Classification, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings